Original Article
Clinical study of ezetimibe combined with rosuvastatin in the treatment of acute myocardial infarction in patients with early onset coronary atherosclerotic heart disease
Yu Jun, Shen Ting, Wang Jinxian, Chen Zhaoshan
Published 2021-10-25
Cite as China Clin Pract Med, 2021, 12(5): 30-33. DOI: 10.3760/cma.j.cn115570-20210412.01055
Abstract
ObjectiveTo analyze the clinical effect of ezetimibe combined with rosuvastatin in the treatment of early onset coronary atherosclerotic heart disease(CHD)acute myocardial infarction.
MethodsA total of 100 patients with acute myocardial infarction with early CHD were enrolled in department of Cardiology in Shanghai Traditional Chinese Medicine Hospital from January 2019 to December 2020, including 54 males and 46 females, aged(56.2±6.3)years old, ranging from 45 to 77 years old.According to the treatment methods, they were divided into ezetimibe group and combination group, with 50 patients in each group.Patients in both groups were treated with conventional treatment measures, ezetimibe group was treated with ezetimibe tablets, and combination group was treated with ezetimibe tablets combined with rosuvastatin tablets.The clinical treatment effect, serum lipid indexes, serum inflammatory factors indexes and the incidence of adverse reactions were compared between the two groups before and after treatment.
ResultsThe total effective rate in the combination group[92.0%(46/50)]was higher than that in the ezetimibe group[76.0%(38/50)], and the difference was statistically significant(χ2=4.762, P=0.029). After treatment, triglycerides[(1.4±0.3)mmol/L]and total cholesterol[(3.0±0.6)mmol/L]in the combination group were lower than those in the ezetimibe group[(2.1±0.5)mmol/L, (4.0±0.8)mmol/L]. Tumor necrosis factor-α[(20.6±5.2)ng/L]and interleukin-6[(120.3±17.5)ng/L]in the combination group were lower than those in the ezetimibe group[(35.4±6.0)ng/L, (161.6±20.5)ng/L], with statistical significance(P<0.05). There was no significant difference in the incidence of adverse reactions between ezeimibe group [8.0%(4/50)]and combination group[6.0%(3/50)], (χ2=1.238, P=0.114).
ConclusionEzetimibe combined with rosuvastatin has high efficacy and safety, can effectively reduce the level of blood lipid in patients with CHD, delay the progression of the disease, so as to improve the treatment effect of acute myocardial infarction, and is worthy of promotion.
Key words:
Ezetimibe; Rosuvastatin; Early onset coronary atherosclerotic heart disease; Acute myocardial infarction
Contributor Information
Yu Jun
Department of Geriatrics, Shanghai Traditional Chinese Medicine Hospital, Shanghai 200071, China
Shen Ting
Department of Geriatrics, Shanghai Traditional Chinese Medicine Hospital, Shanghai 200071, China
Wang Jinxian
Department of Emergency, Shanghai Traditional Chinese Medicine Hospital, Shanghai 200071, China
Chen Zhaoshan
Department of Cardiology, Shanghai Traditional Chinese Medicine Hospital, Shanghai 200071, China
